Navigating the Efficacy & Toxicity Balancing Act: Assessing the TGF-β Therapeutic Window of Opportunity
8:25 am Chair’s Opening Remarks
Looking to the Future: The Opportunities in Novel Strategies to Targeting the TGF-β Pathway
8:30 am Assessing the Window of Opportunity Trials in the Era of Cancer Immunotherapy
Synopsis
- Navigating immunotherapy and early phase clinical trial design
- Illuminating challenges in developing immunotherapies in CNS cancers
- Discussing practical aspects of immunotherapy window of opportunity trials
9:00 am Exploring the Clinical Stage TGF-β Fusion Protein Expressing Oncolytic Virus, AdAPT-001
Synopsis
- Highlighting the safety and tolerability of TGF-β targeting OV, AdAPT-001
- Using correlative studies for measuring expression in the clinic
- Discussing neutralizing TGF-β for improving checkpoint inhibitors
9:30 am Combining TGF-β with Checkpoint Inhibitors to Increase Efficacy as an Immuno-Oncology Therapeutic
Synopsis
- Understanding the rationale for this combination by exploring biomarker data
It Takes Two to Tango: Delving Into TGF-β Combinational Strategies to Balance Toxicity & Efficacy of Immuno-Oncology Therapeutics
10:00 am
Morning Break
11:00 am Looking Outside the Checkpoint Inhibitor World to Radiation & Immunogenic Chemo as an Effective TGF-β Combination
Synopsis
- Evaluating how TGF-β impacts CD8 T cells
- Navigating how radiation and TGF-β therapy synergize
- Highlighting the translation of combination therapy
11:30 am Exploring Translational Approaches as the Key Driver to Validate & Support Combinational Approaches with TGF-β
Synopsis
- Tailoring combinations to phenotypes, the tumor microenvironment, or specific indications
- Defining the considerations of data requirements, data read outs clinically and how to validate a hypothesis non-clinically
12:00 pm
Lunch
1:00 pm Discussion Panel: Debating the Promise of Combinational Strategies with TGF-β
Diving into Delivery & Modality Approaches to Improve the Therapeutic Index for TGF-β Immuno-Oncology Drug Development
1:30 pm Analyzing How SYN101, An Immune Cell Targeted TGF-β Inhibitor, Selectively Blocks Immune Suppression & Restores Tumor Clearance In Vitro & In Vivo
Synopsis
- Highlighting TGF-β is one of the most immunosuppressive cytokines in cancers
- Illuminating SYN-101 as a first-in-class, ADC-like molecule that selectively blocks TGF-β mediated immune suppression for cancer patients
- Accentuating that selective blockade of TGF-β signalling in immune cells restores immune function and drives tumor clearance in vivo
2:00 pm Advancing TGF-β Drug Delivery Approaches for Immuno-Oncology
Synopsis
- Session Overview To Be Confirmed
2:30 pm Audience Roundtable Discussions: Unlocking Novel Strategies for More Precise Inhibition of TGF-β
Synopsis
- This session will facilitate in-depth discussion between participants on their topic table of choice; participants will select a topic, discuss and make notes as a table, and then feedback to the chair and group
- Topics of discussion to include: